Alpha-synuclein overexpression can drive microbiome dysbiosis in mice
Timothy Robert Sampson, Zachary D Wallen, Woong-Jai Won, David George Standaert, Haydeh Payami, Ashley S. Harms.
https://www.biorxiv.org/content/10.1101/2024.02.01.578464v1doi: https://doi.org/10.1101/2024.02.01.578464

Population fraction of Parkinson’s disease attributable to preventable risk factors
Haydeh Payami, Gwendolyn Cohen, Charles F Murchison, Timothy R Sampson, David G Standaert, Zachary D Wallen.
NPJ Parkinsons Dis 2023 Dec 5;9(1):159. doi: 10.1038/s41531-023-00603-z.

Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms
Wallen ZD, Demirkan A, Twa G, Cohen G, Dean MN, Standaert DG, Sampson TR, Payami H. Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms. Nat Commun 13, 6958 (2022). https://doi.org/10.1038/s41467-022-34667-x

Exploring human-genome gut-microbiome interaction in Parkinson’s disease.
Wallen ZD, Stone WJ, Factor SA, Molho E, Zabetian CP, Standaert DG, Payami H.
NPJ Parkinsons Dis. 2021 Aug 18;7(1):74. doi: 10.1038/s41531-021-00218-2. PMID: 34408160; PMCID: PMC8373869.

Comparison study of differential abundance testing methods using two large Parkinson disease gut microbiome datasets derived from 16S amplicon sequencing
Wallen ZD.
BMC Bioinformatics 22, 265 (2021). https://doi.org/10.1186/s12859-021-04193-6

Large-scale association analyses identify host factors influencing human gut microbiome composition.
Alexander Kurilshikov, Carolina Medina-Gomez, Rodrigo Bacigalupe, Djawad Radjabzadeh, Jun Wang, Ayse Demirkan, Caroline I. Le Roy, Juan Antonio Raygoza Garay, Casey T. Finnicum, Xingrong Liu, Daria V. Zhernakova, Marc Jan Bonder, Tue H. Hansen, Fabian Frost, Malte C. Rühlemann, Williams Turpin, Jee-Young Moon, Han-Na Kim, Kreete Lüll, Elad Barkan, Shiraz A. Shah, Myriam Fornage, Joanna Szopinska-Tokov, Zachary D. Wallen, Dmitrii Borisevich, Lars Agreus, Anna Andreasson, Corinna Bang, Larbi Bedrani, Jordana T. Bell, Hans Bisgaard, Michael Boehnke, Dorret I. Boomsma, Robert D. Burk, Annique Claringbould, Kenneth Croitoru, Gareth E. Davies, Cornelia M. van Duijn, Liesbeth Duijts, Gwen Falony, Jingyuan Fu, Adriaan van der Graaf, Torben Hansen, Georg Homuth, David A. Hughes, Richard G. Ijzerman, Matthew A. Jackson, Vincent W. V. Jaddoe, Marie Joossens, Torben Jørgensen, Daniel Keszthelyi, Rob Knight, Markku Laakso, Matthias Laudes, Lenore J. Launer, Wolfgang Lieb, Aldons J. Lusis, Ad A. M. Masclee, Henriette A. Moll, Zlatan Mujagic, Qi Qibin, Daphna Rothschild, Hocheol Shin, Søren J. Sørensen, Claire J. Steves, Jonathan Thorsen, Nicholas J. Timpson, Raul Y. Tito, Sara Vieira-Silva, Uwe Völker, Henry Völzke, Urmo Võsa, Kaitlin H. Wade, Susanna Walter, Kyoko Watanabe, Stefan Weiss, Frank U. Weiss, Omer Weissbrod, Harm-Jan Westra, Gonneke Willemsen, Haydeh Payami, Daisy M. A. E. Jonkers, Alejandro Arias Vasquez, Eco J. C. de Geus, Katie A. Meyer, Jakob Stokholm, Eran Segal, Elin Org, Cisca Wijmenga, Hyung-Lae Kim, Robert C. Kaplan, Tim D. Spector, Andre G. Uitterlinden, Fernando Rivadeneira, Andre Franke, Markus M. Lerch, Lude Franke, Serena Sanna, Mauro D’Amato, Oluf Pedersen, Andrew D. Paterson, Robert Kraaij, Jeroen Raes & Alexandra Zhernakova.
Nat Genet (2021). https://doi.org/10.1038/s41588-020-00763-1

Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.
Wallen ZD, Appah M, Dean MN, Sesler CL, Factor SA, Molho E, Zabetian CP, Standaert DG, Payami H.
NPJ Parkinsons Dis. 2020 Jun 12;6:11. doi: 10.1038/s41531-020-0112-6. eCollection 2020. PMID: 32566740

Plasticity-related gene 3 (LPPR1) and age at diagnosis of Parkinson disease.
Wallen ZD, Chen H, Hill-Burns EM, Factor SA, Zabetian CP, Payami H.
Neurol Genet. 2018 Oct 5;4(5):e271. doi: 10.1212/NXG.0000000000000271. eCollection 2018 Oct. PMID: 30338293

Meta-analysis of human genome-microbiome association studies: the MiBioGen consortium initiative.
Wang J, Kurilshikov A, Radjabzadeh D, Turpin W, Croitoru K, Bonder MJ, Jackson MA, Medina-Gomez C, Frost F, Homuth G, Rühlemann M, Hughes D, Kim HN; MiBioGen Consortium Initiative, Spector TD, Bell JT, Steves CJ, Timpson N, Franke A, Wijmenga C, Meyer K, Kacprowski T, Franke L, Paterson AD, Raes J, Kraaij R, Zhernakova A.
Microbiome. 2018 Jun 8;6(1):101. doi: 10.1186/s40168-018-0479-3. PMID: 29880062

Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson’s Disease.
Houser MC, Chang J, Factor SA, Molho ES, Zabetian CP, Hill-Burns EM, Payami H, Hertzberg VS, Tansey MG.
Mov Disord. 2018 May;33(5):793-804. doi: 10.1002/mds.27326. Epub 2018 Mar 23. PMID: 29572994

The emerging science of precision medicine and pharmacogenomics for Parkinson’s disease.
Payami H.
Mov Disord. 2017 Aug;32(8):1139-1146. doi: 10.1002/mds.27099. Epub 2017 Jul 7. PMID: 28686320

Parkinson’s disease and Parkinson’s disease medications have distinct signatures of the gut microbiome.
Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho E, Zabetian CP, Knight R, Payami H.
Mov Disord. 2017 May;32(5):739-749. doi: 10.1002/mds.26942. Epub 2017 Feb 14. PMID: 28195358

Identification of genetic modifiers of age-at-onset for familial Parkinson’s disease.
Hill-Burns EM, Ross OA, Wissemann WT, Soto-Ortolaza AI, Zareparsi S, Siuda J, Lynch T, Wszolek ZK, Silburn PA, Mellick GD, Ritz B, Scherzer CR, Zabetian CP, Factor SA, Breheny PJ, Payami H.
Hum Mol Genet. 2016 Sep 1;25(17):3849-3862. doi: 10.1093/hmg/ddw206. Epub 2016 Jul 11. PMID: 27402877

Glutamate receptor gene GRIN2A, coffee, and Parkinson disease.
Hamza TH, Hill-Burns EM, Scott WK, Vance JM, Factor SA, Zabetian CP, Payami H.
PLoS Genet. 2014 Nov 20;10(11):e1004774. doi: 10.1371/journal.pgen.1004774. eCollection 2014 Nov. PMID: 25411979

Identification of a novel Parkinson’s disease locus via stratified genome-wide association study.
Hill-Burns EM, Wissemann WT, Hamza TH, Factor SA, Zabetian CP, Payami H.
BMC Genomics. 2014 Feb 10;15:118. doi: 10.1186/1471-2164-15-118. PMID: 24511991

Promise of pharmacogenomics for drug discovery, treatment and prevention of Parkinson’s disease. A perspective.
Payami H, Factor SA.
Neurotherapeutics. 2014 Jan;11(1):111-6. doi: 10.1007/s13311-013-0237-y. PMID: 24258196

Association of Parkinson disease with structural and regulatory variants in the HLA region.
Wissemann WT, Hill-Burns EM, Zabetian CP, Factor SA, Patsopoulos N, Hoglund B, Holcomb C, Donahue RJ, Thomson G, Erlich H, Payami H.
Am J Hum Genet. 2013 Nov 7;93(5):984-93. doi: 10.1016/j.ajhg.2013.10.009. Epub 2013 Oct 31. PMID: 24183452

Evidence for more than one Parkinson’s disease-associated variant within the HLA region.
Hill-Burns EM, Factor SA, Zabetian CP, Thomson G, Payami H.
PLoS One. 2011;6(11):e27109. doi: 10.1371/journal.pone.0027109. Epub 2011 Nov 9. PMID: 22096524

Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson’s disease modifier gene via interaction with coffee.
Hamza TH, Chen H, Hill-Burns EM, Rhodes SL, Montimurro J, Kay DM, Tenesa A, Kusel VI, Sheehan P, Eaaswarkhanth M, Yearout D, Samii A, Roberts JW, Agarwal P, Bordelon Y, Park Y, Wang L, Gao J, Vance JM, Kendler KS, Bacanu SA, Scott WK, Ritz B, Nutt J, Factor SA, Zabetian CP, Payami H.
PLoS Genet. 2011 Aug;7(8):e1002237. doi: 10.1371/journal.pgen.1002237. Epub 2011 Aug 18. PMID: 21876681

Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease.
Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, Kusel VI, Collura R, Roberts J, Griffith A, Samii A, Scott WK, Nutt J, Factor SA, Payami H.
Nat Genet. 2010 Sep;42(9):781-5. doi: 10.1038/ng.642. Epub 2010 Aug 15. PMID: 20711177

The heritability of risk and age at onset of Parkinson’s disease after accounting for known genetic risk factors.
Hamza TH, Payami H.
J Hum Genet. 2010 Apr;55(4):241-3. doi: 10.1038/jhg.2010.13. Epub 2010 Mar 5. PMID: 20203693

Visualizing disease associations: graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer’s and Parkinson’s disease.
Payami H, Kay DM, Zabetian CP, Schellenberg GD, Factor SA, McCulloch CC.
Genet Epidemiol. 2010 Jan;34(1):92-9. doi: 10.1002/gepi.20439. PMID: 19582778

Genetic association between alpha-synuclein and idiopathic Parkinson’s disease.
Kay DM, Factor SA, Samii A, Higgins DS, Griffith A, Roberts JW, Leis BC, Nutt JG, Montimurro JS, Keefe RG, Atkins AJ, Yearout D, Zabetian CP, Payami H.
Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 5;147B(7):1222-30. doi: 10.1002/ajmg.b.30758. PMID: 18404644

Exploring gene-environment interactions in Parkinson’s disease.McCulloch CC, Kay DM, Factor SA, Samii A, Nutt JG, Higgins DS, Griffith A, Roberts JW, Leis BC, Montimurro JS, Zabetian CP, Payami H.
Hum Genet. 2008 Apr;123(3):257-65. doi: 10.1007/s00439-008-0466-z. Epub 2008 Jan 22. PMID: 18210157

Combined effects of smoking, coffee, and NSAIDs on Parkinson’s disease risk.
Powers KM, Kay DM, Factor SA, Zabetian CP, Higgins DS, Samii A, Nutt JG, Griffith A, Leis B, Roberts JW, Martinez ED, Montimurro JS, Checkoway H, Payami H.
Mov Disord. 2008 Jan;23(1):88-95. doi: 10.1002/mds.21782. PMID: 17987647

Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson’s disease.
Zabetian CP, Hutter CM, Factor SA, Nutt JG, Higgins DS, Griffith A, Roberts JW, Leis BC, Kay DM, Yearout D, Montimurro JS, Edwards KL, Samii A, Payami H.
Ann Neurol. 2007 Aug;62(2):137-44. doi: 10.1002/ana.21157. PMID: 17514749

Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson’s disease.
Kay DM, Bird TD, Zabetian CP, Factor SA, Samii A, Higgins DS, Nutt J, Roberts JW, Griffith A, Leis BC, Montimurro JS, Philpott S, Payami H.
Genet Test. 2006 Fall;10(3):221-7. doi: 10.1089/gte.2006.10.221. PMID: 17020475

LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago.
Zabetian CP, Hutter CM, Yearout D, Lopez AN, Factor SA, Griffith A, Leis BC, Bird TD, Nutt JG, Higgins DS, Roberts JW, Kay DM, Edwards KL, Samii A, Payami H.
Am J Hum Genet. 2006 Oct;79(4):752-8. doi: 10.1086/508025. Epub 2006 Aug 17. PMID: 16960813

Analysis of the LRRK2 G2019S mutation in Alzheimer Disease.
Zabetian CP, Lauricella CJ, Tsuang DW, Leverenz JB, Schellenberg GD, Payami H.
Arch Neurol. 2006 Jan;63(1):156-7. doi: 10.1001/archneur.63.1.156. PMID: 16401756

Parkinson’s disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics.
Kay DM, Zabetian CP, Factor SA, Nutt JG, Samii A, Griffith A, Bird TD, Kramer P, Higgins DS, Payami H.
Mov Disord. 2006 Apr;21(4):519-23. doi: 10.1002/mds.20751. PMID: 16250030

One step closer to fixing association studies: evidence for age- and gender-specific allele frequency variations and deviations from Hardy-Weinberg expectations in controls.
Payami H, Zhu M, Montimurro J, Keefe R, McCulloch CC, Moses L.
Hum Genet. 2005 Dec;118(3-4):322-30. doi: 10.1007/s00439-005-0057-1. Epub 2005 Sep 28. PMID: 16189709

Escaping Parkinson’s disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation.
Kay DM, Kramer P, Higgins D, Zabetian CP, Payami H.
Mov Disord. 2005 Aug;20(8):1077-8. doi: 10.1002/mds.20618. PMID: 16001413

False-positive SCA8 gene test in a patient with pathologically proven multiple system atrophy.
Factor SA, Qian J, Lava NS, Hubbard JD, Payami H.
Ann Neurol. 2005 Mar;57(3):462-3. doi: 10.1002/ana.20389. PMID: 15732096

Parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism.
Poorkaj P, Moses L, Montimurro JS, Nutt JG, Schellenberg GD, Payami H.
BMC Neurol. 2005 Feb 22;5(1):4. doi: 10.1186/1471-2377-5-4. PMID: 15725358

SCA2 may present as levodopa-responsive parkinsonism.
Payami H, Nutt J, Gancher S, Bird T, McNeal MG, Seltzer WK, Hussey J, Lockhart P, Gwinn-Hardy K, Singleton AA, Singleton AB, Hardy J, Farrer M.
Mov Disord. 2003 Apr;18(4):425-9. doi: 10.1002/mds.10375. PMID: 12671950

Familial aggregation of Parkinson disease: a comparative study of early-onset and late-onset disease.
Payami H, Zareparsi S, James D, Nutt J.
Arch Neurol. 2002 May;59(5):848-50. doi: 10.1001/archneur.59.5.848. PMID: 12020270

Age at onset of Parkinson disease and apolipoprotein E genotypes.
Zareparsi S, Camicioli R, Sexton G, Bird T, Swanson P, Kaye J, Nutt J, Payami H.
Am J Med Genet. 2002 Jan 15;107(2):156-61. doi: 10.1002/ajmg.10111. PMID: 11807891